Figure S1-S4, Table S1-S7 from An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline <i>BRCA1/2</i> Mutation and Platinum-sensitive Recurrent Ovarian CancerNing Li, Lingying Wu, Qi Zhou et al.|Unknown|2023Cited by 0
Figure S1-S4, Table S1-S7 from An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline <i>BRCA1/2</i> Mutation and Platinum-sensitive Recurrent Ovarian CancerNing Li, Lingying Wu, Hualei Bu et al.|Unknown|2023Cited by 0